% | $
Quotes you view appear here for quick access.

Cytokinetics, Incorporated Message Board

  • nidan7500 nidan7500 Jun 22, 2013 10:35 AM Flag

    Most of what you need to know...from CYTK

    "The company also holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing Tirasemtiv and CK-2127107, which are skeletal muscle activators, as potential treatments for diseases and medical conditions associated with aging, muscle wasting, or neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment, in which treatment with tirasemtiv produced potentially clinically relevant pharmacodynamic effects in Phase II trials. The company has a strategic alliance with Amgen Inc"

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ALS has not had a drug approved in 20+ years...Feb 25 the FDA held a public meeting with the ALS community as the cry for treatments for this always fatal disease go unmet.
      While "T" does not slow progression, it improves quality of life...and will likely show in phase III that it prolonged life as much as the current FDA approved rilutek that only prolongs life 1-3 months.
      With ALS ...there is a life expectancy of only 2-5 years...
      We do not have the time to endure a PhaseIII has proven safe...and imho is very effective in improving strength....
      Imho and with the help off the entire ALS community we want this drug its not just the company ...its the unmet need...40 thousand patients in the US ...300 thousand around the world...screaming at the top of their diminishing lungs.....Treat Us Now

      Sentiment: Strong Buy

8.08-0.08(-0.98%)May 5 4:00 PMEDT